Biofrontera Inc
BFRI1.020USD
-0.020-1.91%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
9.05MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biofrontera Inc Unternehmen
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Unternehmensinformationen
BörsenkürzelBFRI
Name des UnternehmensBiofrontera Inc
IPO-datumOct 14, 2021
CEOProf. Dr. Hermann Luebbert, Ph.D.
Anzahl der mitarbeiter92
WertpapierartOrdinary Share
GeschäftsjahresendeOct 14
Addresse120 Presidential Way,
StadtWOBURN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl01801
Telefon17812451325
Websitehttps://www.biofrontera-us.com/
BörsenkürzelBFRI
IPO-datumOct 14, 2021
CEOProf. Dr. Hermann Luebbert, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
15.21K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
15.21K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2024
FY2023
FY2022
FY2021
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
37.32M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
AIGH Capital Management, LLC.
9.68%
Rosalind Advisors, Inc.
6.82%
Hewlett Fund, L.P.
5.82%
Biofrontera AG
4.23%
Worth Venture Partners, LLC
3.96%
Other
69.48%
Aktionäre
Aktionäre
Anteil
AIGH Capital Management, LLC.
9.68%
Rosalind Advisors, Inc.
6.82%
Hewlett Fund, L.P.
5.82%
Biofrontera AG
4.23%
Worth Venture Partners, LLC
3.96%
Other
69.48%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
10.43%
Private Equity
10.30%
Corporation
10.06%
Investment Advisor/Hedge Fund
4.39%
Individual Investor
3.41%
Investment Advisor
0.82%
Research Firm
0.20%
Other
60.40%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
43
3.55M
37.60%
-1.41M
2025Q1
47
3.28M
35.88%
-1.71M
2024Q4
48
3.72M
54.29%
+158.24K
2024Q3
43
3.76M
68.24%
+377.12K
2024Q2
45
3.39M
76.90%
-69.63K
2024Q1
45
3.44M
88.71%
+1.56M
2023Q4
40
853.94K
58.17%
+32.52K
2023Q3
43
649.68K
47.81%
-61.68K
2023Q2
41
673.17K
109.72%
-35.12K
2023Q1
40
667.34K
54.59%
-30.23K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AIGH Capital Management, LLC.
914.21K
9.68%
+556.50K
+155.57%
Apr 22, 2025
Rosalind Advisors, Inc.
644.39K
6.82%
--
--
Apr 22, 2025
Hewlett Fund, L.P.
550.22K
5.82%
-97.23K
-15.02%
Apr 22, 2025
Biofrontera AG
400.00K
4.23%
--
--
Dec 20, 2024
Worth Venture Partners, LLC
374.44K
3.96%
-70.34K
-15.82%
Mar 31, 2025
Lytton (Laurence W)
306.70K
3.25%
-228.98K
-42.75%
Mar 31, 2025
Armistice Capital LLC
291.15K
3.08%
+141.15K
+94.10%
Sep 30, 2024
Matejka & Partner Asset Management GmbH
63.80K
0.68%
--
--
Nov 30, 2024
Deutsche Balaton Aktiengesellschaft
58.88K
0.62%
+58.88K
--
Dec 20, 2024
Geode Capital Management, L.L.C.
40.14K
0.42%
+20.84K
+107.96%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Datum
Art
Verhältnis
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
